Due to the diverse genomic aberrations in prostate cancer, multiple targeted therapies are being investigated for advanced prostate cancer, such as androgen receptor antagonists [5], AKT inhibitors [6], and PARP inhibitors [7]. This evidence concerns the gene AKT1 and Familial prostate cancer.